Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Sacubitril/valsartan
Other

Sacubitril/valsartan

Tracked across 1 events · 6 articles · First seen Aug 13, 2026 · Last active Aug 13, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 60
Regulatory
Novartis wins UK Entresto patent case
On August 13, 2026, London's United Kingdom — High Court of Justiciary ruled in favor of Swiss drugmaker Novartis in a patent dispute over its blockbuster heart drug Sacubitril/valsartan. Judge Richard Meade rejected a challenge…
Impact: Sacubitril/valsartan is the blockbuster heart drug at the center of the dispute; the ruling upholds its patent protection in the UK, securing its market exclusivity and revenue for Novartis.
Aug 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Sacubitril/valsartan live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.